Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a well-differentiated pancreatic neuroendocrine tumour (a specific, slower-growing type of pancreatic tumour) that was surgically removed between 14 and 120 days before joining the trial
• People who had a scan within the past 90 days showing no signs of the cancer having spread to other parts of the body (using certain types of specialised scans)
• People whose surgery aimed to remove all visible cancer, either completely or nearly completely, as assessed by their surgeon or pathology report
• People who had a specific lab test called Ki-67 (which measures how quickly cancer cells are growing) done between 14 and 90 days before joining, with a result between 3% and 55%
• People whose tumour meets a minimum risk score of 3 or higher based on a scoring system that considers: symptoms caused by the tumour such as bleeding, jaundice, bowel blockage, pain, or pancreatitis (1 point); primary tumour larger than 2 cm (2 points); Ki-67 between 3% and 20% (1 point); cancer found in at least one lymph node (1 point); or Ki-67 between 21% and 55% (6 points)
• People who may have also had up to 5 small areas of cancer in the liver removed or destroyed at the same time as their main surgery
• People who have recovered from their surgery, as determined by their treating doctor
• People aged 18 or older
• People who are generally able to carry out daily activities, with a functional ability score of 0–2 on a standard medical scale (ranging from fully active to capable of limited self-care) (confirm with trial site)
• People who have had a full medical check-up and physical exam within 28 days before joining
• People whose recent blood test results (within 28 days) show adequate white blood cell, neutrophil, and platelet counts, as well as acceptable kidney and liver function levels (confirm with trial site for specific values)
• People who are able to swallow tablets or capsules
• People who are able to have CT or MRI scans, including the use of contrast dye
• People with no other current cancer, or whose previous cancer has been fully treated — with exceptions for certain skin cancers, early-stage cervical cancer, certain early-stage cancers now in full remission, or any cancer from which the person has been cancer-free for at least two years
• People who have been fully informed about the nature of the study and have signed a consent form

Who may not be able to join:

• People who still have cancer that was not fully removed or destroyed during surgery
• People who have cancer that has spread to the brain or the lining around the brain
• People who received treatment for their pancreatic neuroendocrine tumour before surgery (note: the use of a medication class called somatostatin analogues before surgery is permitted)
• People who have already received somatostatin analogue medication after their surgery
• People who plan to take the blood-thinning medication warfarin during the trial (other blood thinners may be acceptable)
• People who have had an allergic reaction to medications similar in composition to temozolomide or capecitabine, which are the study drugs used in this trial
• People who have known problems absorbing medications through their digestive system
• People who have had a serious arterial blood clot event, unstable chest pain (angina), or a heart attack within the 12 months before joining
• People with an active or uncontrolled infection
• People with serious medical or mental health conditions that their treating doctor believes would affect their ability to safely participate
• People who are pregnant, as the study treatments may be harmful to an unborn baby — people of reproductive potential must agree to use effective contraception during the trial, as outlined in the consent process

Important: Always verify eligibility with the trial site directly before applying.